Effect of the EndoBarrier G astrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta‐analysis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Compared with bariatric surgery, less invasive and reversible techniques to counteract obesity and type 2 diabetes ( T2D ) have been developed, including the EndoBarrier G astrointestinal L iner [duodenal‐jejunal bypass sleeve ( DJBS )]. We conducted a systematic review and meta‐analyses of eligible trials to evaluate the efficacy and safety of the DJBS . Five randomized controlled trials ( RCTs ; 235 subjects) and 10 observational studies (211 subjects) were included. The risk of bias was evaluated as high in all studies. The mean body mass index ranged from 30 to 49.2 kg/m 2 and 10–100% of the subjects had T2D . Meta‐analysis showed that the DJBS was associated with significant mean differences in body weight and excess weight loss of −5.1 kg [95% confidence interval ( CI ) −7.3, −3.0; four trials; n = 151; I 2 = 37%] and 12.6% (95% CI 9.0, 16.2; four trials; n = 166; I 2 = 24%), respectively, compared with diet modification. The mean differences in glycated haemoglobin (−0.9%; 95% CI −1.8, 0.0) and fasting plasma glucose (−3.7 mM ; 95% CI −8.2, 0.8) among subjects with T2D did not reach statistical significance. Adverse events consisted mainly of abdominal pain, nausea and vomiting. No deaths occurred. Future high‐quality long‐term RCTs are needed to further assess efficacy and safety.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 3-Year Outcomes
Schauer, P. R., Bhatt, D. L., Kirwan, J. P., Wolski, K., Brethauer, S. A., Navaneethan, S. D., Aminian, A., Pothier, C. E., Kim, E. S. H., Nissen, S. E., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1401329 · Cited by 1,901 · cited 1×
“It has been reported that, after bariatric surgery (RYGB), patients achieve weight losses of up to 40% EWL [27], attain diabetes remission [28] and lower their usage of antidiabetic medication [29].”
BackgroundSjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Chang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688
Sjöström, L., Peltonen, M., Jacobson, P., Ahlin, S., Andersson-Assarsson, J., Anveden, Å., Bouchard, C., Carlsson, B., Karason, K., Lönroth, H., et al. (2014) · JAMA · doi:10.1001/jama.2014.5988 · Cited by 1,054 · cited 1×
“It has been reported that, after bariatric surgery (RYGB), patients achieve weight losses of up to 40% EWL [27], attain diabetes remission [28] and lower their usage of antidiabetic medication [29].”
Background
Cited by
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0236 · Cited by 1,008
“Small human studies have examined numerous approaches, including space-occupying endoluminal devices (90), gastric electrical stimulation (91), duodenal and gastroduodenal endoluminal barriers (92,93), and duodenal mucosal resurfacing (clinical trial reg.”
BackgroundThe role of bariatric surgery to treat diabetes: current challenges and perspectives
Koliaki, C., Liatis, S., le Roux, C. W., & Kokkinos, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0202-6 · Cited by 167
Rubino, F., Nathan, D. M., Eckel, R. H., Schauer, P. R., Alberti, K. G. M. M., Zimmet, P. Z., Del Prato, S., Ji, L., Sadikot, S. M., Herman, W. H., et al. (2016) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2016.05.018 · Cited by 157
Non-pharmacological Treatment Options in the Management of Diabetes Mellitus
Raveendran, A. V. (2018) · European Endocrinology · doi:10.17925/ee.2018.14.2.31 · Cited by 122
“9% respectively, were observed in a recent meta-analysis examining five RCTs and 10 observational studies involving 446 patients treated by this technique.(105)”
BackgroundAuthors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Metadata
- Authors
- Rohde, U., Hedbäck, N., Gluud, L. L., Vilsbøll, T., & Knop, F. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-01-15
- Volume
- 18
- Issue
- 3
- Pages
- 300-305
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2148293498
- Cited by
- 124
- References
- 4
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.